1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Biodefense Market Analysis By Product (Anthrax, Smallpox, Botulism, Radiation/Nuclear, Ebola, Hemorrhagic Fever) And Segment Forecasts To 2020

Global biodefense market is expected to reach USD 13.33 billion by 2020. Growing R&D investments in the field of biotechnology coupled with increasing threat of bioterrorism and disease outbreaks is expected to drive market growth during the forecast period. Furthermore, presence of favorable government initiatives for instance the Emergency Use Authorization (EUA) is expected to boost market growth. This provision allows products to be marketed without an FDA approval in an emergency. Initiatives undertaken by the governments of developing nations for strengthening their respective biodefense product portfolio is expected to fuel future market growth.

Biodefense against anthrax accounted for the largest market share owing to its inclusion in the class A highest priority pathogen category. This classification has resulted in the presence of extensive R&D investments aimed at new product development for strengthening national stockpiles. The global biodefense against anthrax was valued at over USD 2.0 billion in 2013.

Further key findings from the study suggest:

North American was the most revenue generating region in 2013. Majority of the funding programs are organized by the U.S. based government and private establishments. Moreover, these establishments cater to procurement needs of foreign markets.
The market is majorly governed by the initiatives undertaken in the U.S. The country is the largest revenue contributor and is expected to maintain its market position throughout the forecast period. Moreover, funding received by manufacturers under projects such as BioShield is expected to significantly boost demand over the next six years.
Developed European countries such as Germany and the UK have designated funding policies in place pertaining to biodefense. In Switzerland, there is no set biodefense definition but the NBC (nuclear, biological, chemical) protection and research is carried out in Spiez Laboratory of Federal office for Civil Protection, within the Federal Department of Defense. A total of 12 civilian facilities operate under the Swiss biodefense program.
Key players of this market include Emergent BioSolutions, SIGA Technologies, Xoma Corporation and PharmAthene.
Mergers and acquisitions and participating in government tenders are two key sustainability strategies adopted by market players. For instance, in December, 2014, Emergent BioSolutions announced that it had acquired the EV-035 series of molecules from Evolva Holding SA. The acquisition will further strengthen the company’s biodefense line of products.
For the purpose of this study, Grand View Research has segmented the global biodefense market on the basis of product and region:

Global Biodefense Product Outlook (Revenue, USD Million, 2012 – 2020)
- Anthrax
- Smallpox
- Botulism
- Radiation/Nuclear defense
- Others
Biodefense Regional Outlook (Revenue, USD Million, 2012 – 2020)
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- Asia Pacific
- Japan
- China
- RoW
- Brazil

Table Of Contents

Biodefense Market Analysis By Product (Anthrax, Smallpox, Botulism, Radiation/Nuclear, Ebola, Hemorrhagic Fever) And Segment Forecasts To 2020
Table of Contents

Chapter 1 Executive Summary
Chapter 2 Biodefense Industry Outlook
2.1 Market Segmentation
2.2 Market size and growth prospects
2.3 Biodefense - Market dynamics
2.3.1 Market driver analysis
2.3.1.1 Presence of favorable government initiatives
2.3.1.1.1 Emergency Use Authorization of Medical Products
2.3.1.1.2 Project BioShield Act
2.3.2 Market Restraint Analysis
2.3.2.1 Low market penetration in developing and underdeveloped countries
2.4 Key Opportunities Prioritized
2.6 Biodefense - PESTEL analysis
2.7 Market scenario by type
2.7.1 Biological Defense
2.7.2 Chemical Defense
2.7.2.1 Chemical defense: Product pipeline
2.7.3 Nuclear/Radiological Defense
2.7.3.1 Nuclear/radiological defense: Product pipeline analysis
Chapter 3 Biodefense Product Outlook
3.1 Biodefense market share by product, 2013 and 2020
3.2 Anthrax
3.2.1 Biodefense against anthrax market, 2012 - 2020 (USD Million)
3.3 Smallpox
3.3.1 Biodefense against smallpox market, 2012 - 2020 (USD Million)
3.4 Botulism
3.4.1 Biodefense against botulism market, 2012 - 2020 (USD Million)
3.5 Radiation/ nuclear defense
3.5.1 Biodefense against radiation/nuclear defense market, 2012 - 2020 (USD Million)
3.6 Others
3.6.1 Biodefense against other threats market, 2012 - 2020 (USD Million)
Chapter 4 Biodefense Regional Outlook
4.1 Biodefense market share by region, 2013 and 2020
4.2 North America
4.2.1 North America biodefense market, 2012 - 2020 (USD Million)
4.2.2 U.S. biodefense market, 2012 - 2020 (USD Million)
4.2.3 U.S. biodefense market,2012-2020 (USD Million)
4.2.3.1 U.S. biodefense market, by scenario, 2012 - 2020 (USD Million)
4.2.4 U.S. biodefense market, by source, 2012 - 2020 (USD Million)
4.2.4.1 Federal Agencies
4.2.4.1.1 BioShield Act
4.2.4.1.2 Department of Health and Human Services (HHS)
4.2.4.1.3 Department of Defense (DoD)
4.2.4.1.4 Department of Homeland Security
4.2.4.1.5 Department of Agriculture
4.2.4.1.6 Environmental Protection Agency
4.2.4.1.7 Department of Commerce
4.2.4.2 Other Agencies
4.2.5 Canada biodefense market, 2012 - 2020 (USD Million)
4.3 Europe
4.3.1 Europe biodefense market, 2012-2020 (USD Million)
4.3.2 Germany biodefense market, by product,2012-2020(USD Million)
4.3.3 Germany biodefense market, 2012-2020 (USD Million)
4.3.4 UK biodefense market, by product, 2012-2020 (USD Million)
4.3.5 UK biodefense market, 2012-2020 (USD Million)
4.4 Asia Pacific
4.4.1 Asia Pacific biodefense market, 2012-2020 (USD Million)
4.4.2 Japan biodefense market, 2012-2020 (USD Million)
4.4.3 Japan biodefense market, 2012-2020(USD Million)
4.4.4 China biodefense market, 2012-2020 (USD Million)
4.5 RoW
4.5.1 RoW biodefense market, 2012-2020 (USD Million)
Chapter 5 Competitive Landscape
5.1 Xoma Corporation
5.1.1 Company Overview
5.1.2 Financial Performance
5.1.3 Product Benchmarking
5.1.4 Strategic Initiatives
5.2 PharmAthene
5.2.1 Company Overview
5.2.2 Financial Performance
5.2.3 Product Benchmarking
5.2.4 Strategic Initiatives
5.3 Emergent Biosolutions
5.3.1 Company Overview
5.3.2 Financial Performance
5.3.3 Product Benchmarking
5.3.4 Strategic Initiatives
5.4 Dynavax Technologies Inc.
5.4.1 Company Overview
5.4.2 Financial Performance
5.4.3 Product Benchmarking
5.4.4 Strategic Initiatives
5.5 SIGA Technologies
5.5.1 Company Overview
5.5.2 Financial Performance
5.5.3 Product Benchmarking
5.5.4 Strategic Initiatives
5.6 Elusys Therapeutics
5.6.1 Company Overview
5.6.2 Financial Performance
5.6.3 Product Benchmarking
5.6.4 Strategic Initiatives
5.7 Ichor Medical Systems Inc.
5.7.1 Company Overview
5.7.2 Financial Performance
5.7.3 Product Benchmarking
5.7.4 Strategic Initiatives
5.8 DynPort Vaccine Company LLC
5.8.1 Company Overview
5.8.2 Financial Performance
5.8.3 Product Benchmarking
5.8.4 Strategic Initiatives
5.9 Cleveland BioLabs, Inc.
5.9.1 Company Overview
5.9.2 Financial Performance
5.9.3 Product Benchmarking
5.9.4 Strategic Initiatives
5.10 Bavarian Nordic
5.10.1 Company Overview
5.10.2 Financial Performance
5.10.3 Product Benchmarking
5.10.4 Strategic Initiatives
5.11 Achaogen
5.11.1 Company Overview
5.11.2 Financial Performance
5.11.3 Product Benchmarking
5.11.4 Strategic Initiatives
5.12 Nanotherapeutics, Inc.
5.12.1 Company Overview
5.12.2 Financial Performance
5.12.3 Product Benchmarking
5.12.4 Strategic Initiatives
5.13 Alnylam Pharmaceuticals
5.13.1 Company Overview
5.13.2 Financial Performance
5.13.3 Product Benchmarking
5.14 Major list of biodefense contracts, by market player
Chapter 6 Methodology and Scope
6.1 Research Methodology
6.2 Research Scope and Assumptions
6.3 List of Data Sources


List of Tables

TABLE 1 Biodefense Market - Industry Summary and Critical Success Factors (CSFs)
TABLE 2 Biodefense market, by region, 2012 - 2020 (USD Million)
TABLE 3 U.S. biodefense market, by product, 2012 - 2020 (USD million)
TABLE 4 Biodefense - Key market driver analysis
TABLE 5 Biodefense - Key market restraint analysis
TABLE 6 Biological defense: Product pipeline
TABLE 7 List of pipeline products: Anthrax
TABLE 8 List of pipeline products: Smallpox
TABLE 9 List of pipeline products: Botulism
TABLE 10 List of pipeline products: Radiation/nuclear defense
TABLE 11 List of pipeline products: Other threats
TABLE 12 U.S. biodefense market, by product, 2012 - 2020 (USD Million)
TABLE 13 U.S. biodefense market, by scenario, 2012 - 2020 (USD Million)
TABLE 14 U.S. biodefense market, by source, 2012 - 2020 (USD Million)
TABLE 15 Programs under HHS:
TABLE 16 Programs under DoD:
TABLE 17 Programs under department of homeland security
TABLE 18 Programs under department of agriculture
TABLE 19 Canada biodefense market, by product, 2012 - 2020 (USD Million)
TABLE 20 Germany biodefense market, by product, 2012 - 2020 (USD Million)
TABLE 21 Biodefense program licensed manufacturing sites in the UK
TABLE 22 UK biodefense market, by product, 2012 - 2020 (USD Million)
TABLE 23 Japan biodefense market, by product, 2012 - 2020 (USD Million)
TABLE 24 China biodefense market, by product, 2012 - 2020 (USD Million)
TABLE 25 RoW biodefense market, by product, 2012 - 2020 (USD Million)
TABLE 26 Major list of biodefense contracts, by market player


List of Figures

FIG. 1 Biodefense: Market segmentation
FIG. 2 Global biodefense market, 2012 - 2020 (USD Million)
FIG. 3 Biodefense: Market dynamics
FIG. 4 Key opportunities prioritized
FIG. 5 Biodefense market - Porter's analysis
FIG. 6 Biodefense market - PESTEL analysis
FIG. 7 Biodefense market share by product, 2013 and 2020
FIG. 8 Global anthrax biodefense market, 2012 - 2020 (USD Million)
FIG. 9 Global smallpox biodefense market, 2012 - 2020 (USD Million)
FIG. 10 Global botulism biodefense market, 2012 - 2020 (USD Million)
FIG. 11 Global radiation/nuclear defense market, 2012 - 2020 (USD Million)
FIG. 12 Global biodefense market for other threats, 2012 - 2020 (USD Million)
FIG. 13 Biodefense market share by region, 2013 and 2020
FIG. 14 North America biodefense market , 2012 - 2020 (USD Million)
FIG. 15 U.S. biodefense market , 2012 - 2020 (USD Million)
FIG. 16 Canada biodefense market , 2012 - 2020 (USD Million)
FIG. 17 Europe biodefense market , 2012 - 2020 (USD Million)
FIG. 18 Germany biodefense market , 2012 - 2020 (USD Million)
FIG. 19 UK biodefense market , 2012 - 2020 (USD Million)
FIG. 20 Asia Pacific biodefense market , 2012 - 2020 (USD Million)
FIG. 21 Japan biodefense market , 2012 - 2020 (USD Million)
FIG. 22 China biodefense market , 2012 - 2020 (USD Million)
FIG. 23 RoW biodefense market , 2012 - 2020 (USD Million)

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
2016 Virology and Bacteriology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales and Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

2016 Virology and Bacteriology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales and Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

  • $ 54501
  • Industry report
  • October 2016
  • by Venture Planning Group

This unique 33-country survey from VPGMarketResearch.com contains over 2,100 pages, 875 tables and provides data and analysis not available from any other published source. The survey is designed to assist ...

2016 Infectious Disease Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

2016 Infectious Disease Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

  • $ 54501
  • Industry report
  • October 2016
  • by Venture Planning Group

This unique 33-country survey from VPGMarketResearch.com contains over 2,100 pages, 875 tables and provides data and analysis not available from any other published source. The survey is designed to assist ...

2016 Microbiology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Molecular Diagnostic, Microbial Identification, Antibiotic Susceptibility, Blood Culture, Urine Screening, and Immunodiagnostic Tests

2016 Microbiology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Molecular Diagnostic, Microbial Identification, Antibiotic Susceptibility, Blood Culture, Urine Screening, and Immunodiagnostic Tests

  • $ 47500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,000 pages and 550 tables, and provides granular data and analysis not available from any other published source. The survey is designed ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.